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Abstract We investigated the clinical efﬁcacy and safety
of tocilizumab (a humanized anti-IL-6 receptor antibody)
monotherapy in active rheumatoid arthritis (RA) patients
with an inadequate response to low dose methotrexate
(MTX). In a multicenter, double-blind, randomized, con-
trolled trial, 125 patients were allocated to receive either
tocilizumab 8 mg/kg every 4 weeks plus MTX placebo
(tocilizumab group) or tocilizumab placebo plus MTX
8 mg/week (control group) for 24 weeks. The clinical
responses were measured using the American College of
Rheumatology (ACR) criteria and the Disease Activity
Score in 28 joints. Serum vascular endothelial growth
factor (VEGF) levels were also monitored. At week 24,
25.0% in the control group and 80.3% in the tocilizumab
group achieved ACR20 response. The tocilizumab group
showed superior ACR response criteria over control at all
time points. Additionally, serum VEGF levels were sig-
niﬁcantly decreased by tocilizumab treatment. The overall
incidences of adverse events (AEs) were 72 and 92%
(serious AEs: 4.7 and 6.6%; serious infections: 1.6 and
3.3%) in the control and the tocilizumab groups, respec-
tively. All serious adverse events improved by adequate
treatment. Tocilizumab monotherapy was well tolerated
and provided an excellent clinical beneﬁt in active RA
patients with an inadequate response to low dose MTX.
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Introduction
Rheumatoid arthritis (RA) is a common autoimmune dis-
ease characterized by persistent synovitis and progressive
destruction of cartilage and bone in multiple joints [1]. The
affected joints exhibit hyperplasia of inﬂamed synovium
inﬁltrated with a range of immunocompetent cells, which
forms pannus tissue and invade cartilage and bone [2].
Angiogenesis is a characteristic histological feature of
rheumatoid synovium for which vascular endothelial
growth factor (VEGF) is responsible [3]. In addition,
patients with RA show systemic inﬂammatory manifesta-
tions such as fever, fatigue, anemia, and laboratory
ﬁndings, including elevated erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP), hyper-c-globulinemia
and emergence of various types of autoantibodies. These
abnormalities can be explained, at least partly, by dereg-
ulated overproduction of interleukin (IL)-6, a pro-
inﬂammatory cytokine, although the etiological causes are
not fully understood.
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pro-inﬂammatory cytokines, such as tumor necrosis factor
(TNF)-a, IL-1, have been successfully used in the treat-
ment of RA. However, these therapies are not always
effective. In addition, adverse reactions are also the prob-
lem for those treatments. Therefore, we need further new
therapeutic agents that have a new mechanism of action
and higher efﬁcacy.
Tocilizumab is a humanized anti-human IL-6 receptor
(IL-6R) monoclonal antibody that inhibits IL-6 binding to
IL-6R [4]. This antibody was humanized by grafting the
complementarity-determining regions from a murine anti-
IL-6R antibody into human IgG1, thereby creating a
functioning antigen-binding site in a reshaped human
antibody and reducing the antigenicity of the antibody in
human. We have demonstrated that treatment with toc-
ilizumab improves the signs and symptoms and prevents
joint damage of RA [5–8]. The objective of this clinical
trial was to investigate the safety and efﬁcacy of toc-
ilizumab monotherapy in active RA patients with an
inadequate response to MTX, an anchor drug for RA
treatment, at a dose of 8 mg/week, which is approved for
adult RA patients in Japan. In addition, tocilizumab effect
on serum VEGF levels was also examined.
Patients and methods
Patients
Eligible patients were between 20 and 75 years old, ful-
ﬁlled the American college of Rheumatology (ACR;
formerly, the American Rheumatism Association) 1987
revised criteria for the classiﬁcation of RA [9], with disease
duration of more than 6 months. All candidates were
treated with MTX 8 mg/week for at least 8 weeks until
enrolment. They all had C6 tender joints (of 49 evaluated),
C6 swollen joints (of 46 evaluated), ESR of C30 mm/h or
CRP of C10 mg/l at enrolment. An inadequate response to
MTX was deﬁned as the presence of active disease, as
described above. Patients were not allowed to have
received prior anti-TNF agents or leﬂunomide (within
12 weeks prior to the ﬁrst dose), plasma exchange therapy
or surgical treatments (within 4 weeks prior to the ﬁrst
dose), DMARDs other than MTX or immunosuppressants
(within 2 weeks prior to the ﬁrst dose). Oral corticosteroids
(prednisolone, B10 mg/day) were allowed if the dosage
had not been changed within 2 weeks. Eligible patients had
white blood cell counts C3.5 9 10
9/l, lymphocyte counts
C0.5 9 10
9/l and platelet count of at least the lower limit
of normal as deﬁned by the respective local laboratory
used. Patients were excluded if they had functional class IV
using Steinbrocker’s criteria [10], aspartate transaminase
(AST), alanine transaminase (ALT) and serum creatinine
C1.5-fold the upper limit of normal, were HBs antigen and/
or HCV antibody positive, had pulmonary ﬁbrosis or active
pulmonary disease, a history of serious adverse drug
reaction to MTX, concomitant pleural effusion, ascites,
varicella infection, or were excessive users of alcohol on a
regular basis. Patients were also excluded if they had sig-
niﬁcant cardiac, blood, respiratory system, neurologic,
endocrine, renal, hepatic, or gastrointestinal disease, or had
an active infection requiring medication within 4 weeks
before the ﬁrst dose or medical history of a serious allergic
reaction. Sexually active premenopausal women were
required to have a negative urine pregnancy test at the
entry to the study and to use effective contraception during
the study period.
Study protocol
This study was conducted at 25 sites in Japan. The study
protocol was approved by the Ministry of Health, Labor
and Welfare of Japan, and by the local ethical commit-
tee. Patients gave their written informed consent. This
trial was registered with http://www.clinicaltrials.gov
(NCT00144521). The ﬁrst patient was enrolled on
January 27, 2004, and the last patient exited the study on
February 15, 2005.
Patients were randomly assigned to receive either toc-
ilizumab therapy or MTX therapy as a control: tocilizumab
8 mg/kg every 4 weeks plus MTX placebo (tocilizumab
group) or tocilizumab placebo plus MTX 8 mg/week
(control group) for 24 weeks. The randomization was done
by registering the patients to the patient registration center
utilizing a centralized allocation method. The dosage of
tocilizumab used in this study was chosen according to a
previous dose ﬁnding study [7]. The dose of MTX was the
maximum dose allowed in Japan (see Discussion). Oral
corticosteroids less than 10 mg prednisolone per day were
allowed, and the dose could not be increased during the
study. Intra-articular injections of corticosteroid (only one
joint at one treatment) and hyaluronate preparations were
allowed. Use of one nonsteroidal anti-inﬂammatory drug
(NSAID), including switching to another NSAID, was
allowed. DMARDs, intravenous or intramuscular cortico-
steroids, plasmapheresis and surgical treatment were not
allowed. Patients who received three or more doses of
tocilizumab or tocilizumab placebo were able to join an
open-label extension study of tocilizumab.
The clinical responses were measured using the ACR
criteria as well as the Disease Activity Score in 28 joints
(DAS28) and the European League Against Rheumatism
(EULAR) criteria based on DAS28. Remission was deﬁned
according to EULAR deﬁnition of a DAS28 \2.6 [11].
Serum VEGF levels were also monitored. Safety was
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123assessed through recording of adverse events, physical
examinations, and standard laboratory tests.
Statistical analysis
We determined that a sample size of 57 patients per treat-
ment group was required to provide 90% power for
detecting a signiﬁcant (P\0.05) difference in ACR20
response between the control group and the tocilizumab
group by use of the two-side chi-square test, where ACR20
response rates in the population were assumed to be 35 and
65% in the control group and the tocilizumab group,
respectively. We decided to recruit 60 patients per treatment
group to allow for anticipated withdrawals. The primary
end point was the ACR20 response at week 24 with the last
observation carried forward (LOCF) method, using an
intent-to-treat (ITT) analysis. The incidences of clinical
improvements were analyzed by the chi-square test.
All statistical analyses were two-sided and P values less
than 0.05 were considered signiﬁcant. All patients receiv-
ing at least one dose of tocilizumab or tocilizumab placebo,
and at least 4 weeks of MTX or MTX placebo adminis-
tration were included in the clinical efﬁcacy analysis.
Results
Characteristics of the patients
One-hundred and twenty-seven patients were enrolled in
the study (Fig. 1). Two patients randomized to the control
group withdrew before dosing (gall stone and patient’s
request). A total of 125 patients (64 in the control group
and 61 in the tocilizumab group) received study drugs.
Thirty-three patients in the control group and 54 patients in
the tocilizumab group completed 24-week treatment.
Withdrawal occurred in 31 patients in the control group
and seven patients in the tocilizumab group. The reported
reasons for withdrawal are shown in Fig. 1.
Demographics and baseline disease characteristics did
not differ between the two groups (Table 1). Mean disease
duration was 8.6 years. Patients had active RA, indicated
by DAS28 score of 6.1 and CRP of 31 mg/l at baseline
after using of MTX 8 mg/week for at least 8 weeks.
Clinical efﬁcacy
The primary end point of the study, an ACR20 response at
week 24 was 25.0% in the control group compared with
80.3% in the tocilizumab group, indicating the superiority
of tocilizumab treatment (P\0.001). The ACR50 and
ACR70 response rates in the tocilizumab group were
higher than those in the control group at all time points
from week 4 onward (Fig. 2a). At the last observation, the
ACR50 response rate was 10.9 and 49.2%, and the
ACR70 response rate was 6.3 and 29.5% in the control
group and the tocilizumab group, respectively. Addition-
ally, the tocilizumab group showed a greater reduction in
Fig. 1 Randomization, reasons for withdrawal, and numbers of
patients who completed the trial. Tocilizumab humanized anti-
interleukin-6 receptor antibody
Table 1 Patient demographics and clinical characteristics at baseline
Control group
(n = 64)
Tocilizumab
group
(n = 61)
Demographics
Age (years) 50.8 ± 12.2 52.6 ± 10.6
Male:female ratio 16:48 6:55
Clinical characteristics
RA duration (years) 8.7 ± 7.1 8.5 ± 8.4
No. of failed DMARDs, mean
(range)
3.6 (1–8) 3.3 (1–8)
Functional class
a,
I/II/III/IV
7:50:7:0 2:49:10:0
RA Stage
a, I/II/III/IV 3:18:17:26 1:20:22:18
Tender joint count,
0–49 scale
14.2 ± 8.6 13.8 ± 7.5
Swollen joint count,
0–46 scale
12.7 ± 7.5 12.4 ± 5.9
ESR (mm/h) 51.9 ± 24.0 51.9 ± 27.7
CRP (mg/l) 32 ± 26 30 ± 20
DAS28 6.2 ± 0.9 6.1 ± 0.9
VEGF (pg/ml) 730.8 ± 445.6 711.3 ± 417.4
Except where indicated otherwise values are mean ± SD
Tocilizumab humanized anti-interleukin-6 receptor antibody; RA
rheumatoid arthritis; ESR erythrocyte sedimentation rate; CRP C-
reactive protein; DAS28 Disease Activity Score in 28 joints; VEGF
vascular endothelial growth factor
a RA functional status determined by the American College of
Rheumatology criteria. RA stage determined by Steinbrocker’s
criteria
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123DAS28 than the control group did (Fig. 2b). At the last
observation, the incidence of ‘‘Good’’ was 3.2 and 65.5%,
and that of ‘‘Good or moderate’’ was 39.7 and 96.6% in
the control group and the tocilizumab group, respectively.
Similarly, remission was observed in 1.6% of the control
group and 43.1% of the tocilizumab group at the
last observation, and tocilizumab treatment achieved
signiﬁcantly higher remission rates than MTX treatment
(P\0.001).
Tocilizumab treatment also signiﬁcantly improved
MHAQ scores compared to MTX treatment (Fig. 2c). A
decrease of C0.22 units in MHAQ scores represents sig-
niﬁcant clinical improvement and the minimum clinical
important difference [12]. Such improvement was seen in
34% in the control group and 67% in the tocilizumab group
at the last observation, demonstrating signiﬁcant
improvement in the tocilizumab group compared to the
control group (P\0.001).
The mean serum VEGF levels showed a marked
decrease in the tocilizumab group (Fig. 3). Mean changes
from baseline were -74.0 pg/ml in the control group and
-346.9 pg/ml in the tocilizumab group at week 24
(P\0.001).
Safety
A total of 104 adverse events occurred in 46 of 64 patients
(71.9%) in the control group and 211 adverse events
occurred in 56 of 61 patients (91.8%) in the tocilizumab
group. Most of the adverse events were mild or moderate.
Table 2 shows frequent adverse events observed in at least
5% of the patients. Nasopharyngitis was the most common
adverse event in the both groups (the control group 10.9%,
the tocilizumab group 18.0%).
Serious adverse events were reported in 4.7% (3 of 64
patients) and 6.6% (4 of 61 patients) in the control group
and tocilizumab group, respectively. In the control group,
these consisted of one event each of pneumonia, spinal
compression fracture and femoral neck fracture, among
which a causal relationship with the study drug could not
Fig. 2 Percentage of responders according to the American College
of Rheumatology (ACR) improvement criteria and the Disease
Activity Score in 28 joints (DAS28) as well as mean change in
Modiﬁed Health Assessment Questionnaire (MHAQ) scores. Per-
centage of responders according to the ACR improvement criteria (a)
and the DAS28 (b) according to the ITT analysis over 24 weeks.
Mean change in MHAQ scores from baseline to week 24 (c). Last
OBS = last observation. *P\0.05;  P\0.01;  P\0.001 versus
MTX by paired t-test
Fig. 3 Change from baseline in serum levels of VEGF. Values are
the mean for each group at each time point. VEGF was measured at
three points (0, 12 and 24 weeks) over the study period. Last OBS =
last observation.  P\0.001 versus MTX by paired t-test
Mod Rheumatol (2009) 19:12–19 15
123be ruled out for pneumonia. In the tocilizumab group, the
serious adverse events consisted of one event each of
pneumonia, infectious arthritis, colonic polyp and head-
ache, among which a causal relationship with the
investigational product could not be ruled out for pneu-
monia and infectious arthritis. All serious adverse events
improved with appropriate treatments.
Tuberculosis was not observed in this study. No tuber-
culosis screening or prophylactic use of any anti-
tuberculosis drugs was done for this study.
Drug-related infusion reactions were reported for eight
events in seven patients (11.5%) of the tocilizumab group:
two with pruritus, and one each with headache, ﬂushing,
rash, arthralgia, abnormal feeling and increased blood
pressure. The severity of arthralgia was moderate while all
other infusion reactions were mild, and all patients con-
tinued the study.
Laboratory ﬁndings
Laboratory test abnormalities were reported in 23 and 56%
of patients in the control and the tocilizumab groups,
respectively. In the tocilizumab group, lipid metabolism-
related changes such as an increase in total cholesterol
(TC), triglycerides (TG), and low-density lipoprotein cho-
lesterol (LDLC) were common. Increases in TC, TG, and
LDLC under non-fasting were reported in 36, 20, and 28%
of the patients, respectively. Most of them were grade 1
according to the National Cancer Institute Common Tox-
icity Criteria (NCI-CTC). Values increased until week 4
and thereafter remained constant. High-density lipoprotein
cholesterol (HDLC) values were also raised in the toc-
ilizumab group. Therefore, the atherogenic index,
calculated by (TC-HDLC)/HDLC, did not change at all
throughout the study period of 24 weeks.
Increases in AST, ALT, and total bilirubin were reported
in 8, 11, and 0% of the patients in the control group, and 3,
5, and 2% in the tocilizumab group, respectively. These
values did not continue to be increased, but became stable
at week 16 in the tocilizumab group (Fig. 4). All the
patients with these abnormalities in the tocilizumab group
were NCI-CTC grade 1 except for 1 patient with grade 2
increase in total bilirubin. There was no patient who
withdrew from this study for the reason of liver functional
abnormality.
Anti-tocilizumab antibodies were not detected in this
study.
Discussion
This study was a multi-center, randomized, blinded, dou-
ble-dummy trial of tocilizumab in active RA patients who
had an inadequate response to low dose MTX treatment in
Japan. The results of this study conﬁrmed the excellent
efﬁcacy of tocilizumab monotherapy for signs and symp-
toms as shown in previous studies [7, 8]. Since MTX is an
anchor drug in RA treatment, it is noteworthy that toc-
ilizumab treatment is a very efﬁcacious treatment for the
patients with an inadequate response to MTX. In addition,
switching MTX therapy to tocilizumab monotherapy was
safe and effective.
The dose of MTX prior to enrollment was 10–25 mg/
week in CHARISMA study, which was conducted in
Europe [13], while all patients in this study were treated
with MTX 8 mg/week. The dosage 8 mg of MTX/week in
this trial is the maximum dosage approved in Japan. The
Japanese government recommends 6–8 mg/week of MTX
based on the evidence from the Japanese clinical trials of
MTX for RA [14, 15]. The MTX dosage used in Japan is
lower than that used in Western populations treated in the
EU or US. The average body weight of the patients in this
study was 54 kg, and much lower than those of EU and US
patients. Additionally, all patients were given folic acid in
the CHARISMA study, in contrast to only 51% of the
patients in this study. Considering these factors, the dif-
ferences in the clinical efﬁcacy of MTX between the
CHARISMA study and this study might not be so large as
expected when looking at the difference in the MTX dose.
Maini et al. demonstrated in the CHARISMA study, that
adding MTX to tocilizumab increased the efﬁcacy in terms
of ACR50 and ACR70 response rates, although there was
no difference in ACR20 response rates between the toc-
ilizumab 8 mg/kg monotherapy and the tocilizumab 8 mg/
kg plus MTX. Thus, the combination with MTX may be a
therapeutic option, if the toxicity is not increased. In this
study, however, even monotherapy with tocilizumab 8 mg/
kg induced DAS28 remission at 6 months in about 40% of
patients. Furthermore, since anti-tocilizumab antibodies are
not detected without use of MTX, the combination with
MTX is not required to suppress the emergence of anti-
Table 2 Adverse events observed in at least 5% of patients
Control group
(n = 64)
Tocilizumab group
(n = 61)
Nasopharyngitis 7 (10.9) 11 (18.0)
Stomatitis 0 7 (11.5)
Hyperlipidemia 1 (1.6) 4 (6.6)
Headache 2 (3.1) 4 (6.6)
Rash 2 (3.1) 4 (6.6)
Diarrhea 1 (1.6) 4 (6.6)
Upper respiratory tract
inﬂammation
4 (6.3) 3 (4.9)
Values are the number (%) of patients
Tocilizumab humanized anti-interleukin-6 receptor antibody
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used. Therefore, tocilizumab will be useful for the patients
who do not tolerate MTX.
This double-blind study of tocilizumab also conﬁrms the
previous ﬁnding that IL-6 receptor inhibition improves
serum VEGF levels of RA patients [16]. Serum VEGF
levels markedly decreased during tocilizumab therapy
compared to the treatment with MTX. VEGF is produced
by macrophages, ﬁbroblasts surrounding microvessels,
vascular smooth muscle cells, synovial lining cells in
synovium [17], neutrophils in synovial ﬂuid [18], and
peripheral blood mononuclear cells [19] from patients with
RA. VEGF is a potent angiogenic factor and thought to be
responsible for the angiogenesis necessary to oxygenate the
hypertrophic synovial tissues of the affected joints of RA
patients [20, 21]. VEGF also induces vascular permeability
and mediates inﬂammation [22–24]. Therefore, the
decrease in VEGF may be an important part of the mech-
anism how IL-6 receptor inhibition with tocilizumab exerts
its therapeutic efﬁcacy in RA. Since serum VEGF levels
correlate with disease activity scores and radiographic
progression in RA patients [16, 25], the dramatic decrease
in VEGF also underlines the efﬁcacy of tocilizumab. The
normalization of VEGF by blockade of IL-6 function alone
indicates that IL-6 is essential for the VEGF production in
this disease.
Tocilizumab monotherapy was generally well tolerated.
There was no speciﬁc type of infection related to toc-
ilizumab therapy. There is no indication for an increased
risk of reactivation of latent tuberculosis, which is often a
problem in anti-TNF therapy [26]. In this study patients did
not receive prophylactic medication nor were they screened
for latent or active tuberculosis at the time of screening.
The increase in TC observed is in concordance with
observations in previous studies of tocilizumab [7, 8]. This
may be secondary to the improvement in inﬂammation.
Furthermore, there was no cardiovascular adverse event
related to the increase in TC. However, further investigation
willberequiredtoevaluatewhetherornottocilizumabmight
increase the risk for developing ischemic heart diseases.
The mean value elevations of liver functional tests (AST,
ALT and total bilirubin) were seen in the tocilizumab group
as well as in the control group, but they were within normal
range. Liver functional tests abnormalities were more fre-
quently observed in the control group than in the
tocilizumab group. Moreover, most of them were grade 1
according to the NCI-CTC. These abnormalities were
clinically not signiﬁcant and no hepatitis was observed.
Therefore, tocilizumab monotherapy appears to be as tol-
erable as MTX in terms of liver function.
Conclusion
This study demonstrates that tocilizumab monotherapy in
patients with active RA who had an inadequate response to
Fig. 4 Change from baseline in serum levels of aspartate transam-
inase (AST), alanine transaminase (ALT), total bilirubin (T-BIL).
Values are the mean for each group at each time point
Mod Rheumatol (2009) 19:12–19 17
123low dose MTX treatment in Japan has an excellent efﬁcacy
with a positive beneﬁt-risk ratio.
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